知镜 Cognispect · 医学文献与研究工作台

Efficacy and safety of magnesium glycinate as add on therapy in hypomagnesemic asthma and chronic obstructive pulmonary disease patients: A randomised controlled study assessing inflammatory biomarkers.

Maddirevula MK, Rajanandh MG, Wesley B.
Pulmonary pharmacology & therapeutics · 2026-08-23 · PMID 42633850

文献摘要

Asthma and COPD are chronic respiratory conditions characterised by persistent airway inflammation, elevated inflammatory biomarkers (CRP, TNF-α, IL-6, IL-10), and frequent hypomagnesaemia, which worsens disease severity despite standard treatments. This study evaluates the efficacy and safety of Magnesium glycinate (440 mg/day) as add on therapy in the management of asthma and COPD. This randomised, double-blind, placebo-controlled trial enrolled 224 adults (112 Asthma and 112 COPD) with confirmed hypomagnesemia (Serum magnesium 1 (asthma: +0.23 L, p = 0.002; COPD: +0.19 L, p = 0.004). Alongside an increase in the anti-inflammatory cytokine IL-10 (+2.8 pg/mL, 95% CI + 0.61 to +4.99, p = 0.013) and the intervention was well tolerated with no serious adverse events compared to placebo. Adjunctive magnesium glycinate safely reduces inflammatory biomarkers, particularly CRP, in hypomagnesemic asthma and COPD patients, with stronger cytokine modulation in COPD.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。